Published in final edited form as:

Bone. 2019 June ; 123: 86–91. doi:10.1016/j.bone.2019.03.025.

Targeting Vascular Endothelial Growth Factor Ameliorates PMMA-particles induced Inflammatory Osteolysis in Murine Calvaria.

Wahid Abu-Amer^a, Manoj Arra^a, John C.F. Clohisy^a, Yousef Abu-Amer^{a,b,c,d}, and Gaurav Swarnkar^{a,d,*}

^aDepartment of Orthopaedic Surgery, Washington University School of Medicine, St. Louis MO 63110

^bDepartment of Cell Biology & Physiology, Washington University School of Medicine, St. Louis MO 63110

^cShriners Hospital for Children, St. Louis MO 63110

^dThese are co-senior authors.

Abstract

Cytokines and growth factors mediate inflammatory osteolysis in response to particles released from bone implants. However, the mechanism by which this process develops is not entirely clear. Blood vessels and related factors may be required to deliver immune cells and soluble factors to the injury site. Therefore, in the current study we investigated if, vascular endothelial growth factor (VEGF), which is required for angiogenesis, mediates polymethylmethacrylate (PMMA) particles-induced osteolysis. Using bone marrow derived macrophages (BMMs) and ST2 stromal cell line, we show that PMMA particles increase VEGF expression. Further, using a murine calvarial osteolysis model, we found that PMMA injection over calvaria induce significant increase in VEGF expression as well as new vessel formation, represented by von Willebrand factor (vWF) staining. Co-treatment using a VEGF-neutralizing antibody abrogated expression of vWF, indicating decreased angiogenesis. Finally, VEGF neutralizing antibody reduced expression of Tumor necrosis factor (TNF) and decreased osteoclastogenesis induced by PMMA particles in calvariae. This work highlights the significance of angiogenesis, specifically VEGF, as key driver of PMMA particle-induced inflammatory osteolysis, inhibition of which attenuates this response.

*Corresponding Author: Gaurav Swarnkar, Ph.D. Department of Orthopedic Surgery, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8233, Saint Louis, MO 63110, Phone: (314) 362-8514, Fax: (314) 362-0334, gauravswarnkar@wustl.edu.

Authors Contribution

WA, YA and GS designed research; WA, JC and MA performed research and analyzed data; WA, MA, YA and GS participated in writing the manuscript. All authors have read and approved the final version of the manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest

The authors declare no conflicts of interest.

Keywords

PMMA; Inflammation; osteolysis; osteoclastogenesis; angiogenesis

1. Introduction

Inflammatory osteolysis continues to pose a skeletal health concern especially in chronic settings fueled by the presence of bacteria or particles released from orthopedic implants. In this regard, it has been suggested that wear-debris particles at the bone-cement interface causes an inflammatory osteolytic reaction. Attempts to address these osteolytic processes have mainly targeted osteoclasts due to their bone-resorbing abilities [1]. To understand their role in aseptic loosening, research has turned to the removed implants, which have been associated with the formation of pseudo-membranes at the cement-bone interface. These membranes have been shown to have elevated levels of interleukin-1, tumor necrosis factor- α and prostaglandin E2 [2, 3], both activate the NF- κ B pathway and exacerbate osteoclasts. [4, 5] [6–8].

Vasculature has long been known to play a role in bone metabolism by providing nutrients, minerals, structure, and a desirable environment for hematopoietic stem cell (HSC) growth and differentiation [9]. Recently, blood vessels have been ascribed to angiocrine functions as well, providing paracrine signaling to promote bone growth [10]. Therefore, it is thought that angiogenesis is required for the development, remodeling, and repair of bone tissue. Vascular endothelial growth factor (VEGF) has been recognized as the most important mediator of angiogenesis [11], and has been shown to directly enhance osteoclastic bone resorption and survival of mature osteoclasts [12, 13]. Furthermore, many have shown that VEGF was detected in osteoblasts, osteoclasts, endothelial cells, fibroblasts and macrophages adjacent to bony inflammation [12, 14–16]. This also lends confidence to the thought that VEGF, and therefore angiogenesis, are tied closely to bone metabolism.

It is well established that PMMA debris particles are major players in the induction of implant-induced osteolysis. Further, the close apparent relationship between angiogenesis and osteoclast activity in inflammatory osteolysis suggest that polymethylmethacrylate (PMMA) particles may induce expression of VEGF in osteoclast progenitors and mesenchymal cells to facilitate and enhance the inflammatory microenvironment through promotion of vascular infiltration.

Moreover, it has been demonstrated that when bone marrow osteoclast precursors were treated with VEGF, this directly enhanced their differentiation, survival, and resorptive activities [13, 17]. We have also seen that osteoclasts not only react to VEGF, but also express it, suggesting potential autocrine and paracrine mechanisms. Other studies have demonstrated that osteoclasts express VEGF in a size dependent manner, such that cells with a larger number of nuclei have an elevated level of expression compared to those with a smaller number of nuclei, and that patients with increased osteoarthritis (OA) severity had increased VEGF expression [18, 19]. Furthermore, expression of VEGF was mediated by HIF-1, which in turn mediates RANKL and NF- κ B [18]. In addition, several studies have shown that by blocking the VEGFR using various methods, growth differentiation and

survival of osteoclasts are attenuated, hence restricting the extent of osteolysis. In one report, the use of a VEGFR-targeted tyrosine kinase inhibitor attenuated osteoclast differentiation and cancer-induced bone destruction [20]. In another, intra-articular injections with bevacizumab (a monoclonal IgG1 antibody targeting VEGF) in rabbits with OA showed a reduction in articular cartilage damage, osteophyte formation, and pain [21–23]. These reports highlight the role of VEGF in bone and joint pathology.

Currently, insufficient evidence exists to explain the relationship and effects of PMMA on VEGF expression, osteoclastogenesis, and inflammatory osteolysis in an *in vivo* model. Therefore, the present study seeks to answer several questions: 1) Do PMMA particles promote VEGF expression? 2) Do PMMA particles promote angiogenesis? 3) Does neutralization of VEGF inhibit inflammatory osteolysis? Thus, this work examines the effect of PMMA treatment on VEGF expression in murine bone marrow macrophages and ST2 mesenchymal cells *in vitro*. These studies are paired with studies in a well-established murine calvaria osteolysis model, which mimics the interactions of wear particles and various bone cells seen during aseptic loosening of orthopedic implants in humans. In this model we investigated the *in vivo* effects of PMMA on the expression of VEGF, and other angiogenic factors in the calvaria and the utility of VEGF neutralizing antibody to inhibit PMMA-mediated osteolysis.

2. Material and methods

2.1. Polymethylmethacrylate (PMMA) particles

Microsphere PMMA particles (Polysciences) 1–10 μm in diameter were used for all experiments as previously reported. PMMA particles, were first washed in ethanol four times, followed by overnight incubation in ethanol for sterilization, and then washed four times with PBS. Particles were later resuspended in serum-free MEM and stored at 4°C. For *in vitro* experiments the cells were treated with 100 $\mu\text{g/ml}$ of PMMA particles.

2.2. Cell culture

ST2 cells were cultured in RPMI 1640 culture media supplemented with 100 units/ml penicillin/streptomycin and 10% FBS (v/v) (Gibco, Thermo Fisher Scientific). Bone marrow macrophages (BMMs) were differentiated from bone marrow cells (BMCs) isolated from tibiae and femurs of 2-month-old mice. Bone marrow cells were cultured in α -MEM supplemented with 100 units/ml penicillin/streptomycin and 10% FBS (v/v) with 10 ng/ml M-CSF for 16 h to separate adherent cells from non-adherent cells. Non-adherent cells were collected and further cultured with M-CSF (20 ng/ml) for 3 to 4 days to generate bone marrow macrophages.

2.3. Immunoblotting

ST2 cells and BMM were treated with PMMS (0.1% w/v) different time points. Total cell lysates were prepared in cell lysis buffer (Cell Signaling Technology) containing protease and phosphatase inhibitors (ThermoFischer). Equal amount of proteins as determined by BCA kit were subjected to western blotting. Membranes were probed with VEGF primary antibody (R&D) and Actin (Sigma).

2.4. Animals

8–10 weeks old C57BL/6 wild type male and female mice (at approximate equal ratios) were, housed at the Washington University School of Medicine barrier facility. The mice were kept at 12 hours day and night cycle with free access to water and food. All experimental protocols were carried out in accordance with the animal ethical guidelines approved by the Washington University School of Medicine Institutional Animal Care and Use Committee (IACUC). To induce calvarial osteolysis mice (n=10) were injected with 100ul of PMMA particles (1mg/100ul of PBS) over the calvarium. Corresponding control mice were injected with PBS only. At the same time mice were randomly divided and were administered with or without IgG (n=5) or VEGF neutralizing antibody (AF-493-NA; R&D) (SC, 0.1mg/KgBW/daily) (n=5). The murine model of calvarial osteolysis is a well-established model to study aseptic loosening of joints with no adverse effect to the animals over a short period of PMMA administration. After 8 days, mice were sacrificed using CO₂ asphyxiation and the calvariae were collected from different groups for histological analysis.

2.5. Histology

At the end of the experiment the mice were sacrificed and the calvariae were surgically removed, preserved in 10% buffered formalin (24 hrs), and decalcified using 10% EDTA, pH 7.0 for 7 days. Calvariae were then dehydrated in graded alcohol, cleared through xylene and embedded in paraffin. Paraffin blocks were sectioned longitudinally. Five-micron sections were then stained for either tartrate-resistant acid phosphatase (TRAP) or for TNF, VEGF and von Willebrand Factor (vWF).

2.6. Data Analysis:

The *in vitro* western blot images represent three independent experiments with similar findings. For *in vivo* experiments, 5 animals were used in each treatment group. At the end of the treatment, all the animals were sacrificed and the calvariae were used for histology. The images were analyzed double blinded for qualitative assessment of staining and osteolysis. The photomicrographs represents the analysis of five calvariae sections from different animals.

3. Results

3.1. PMMA particles induce expression of VEGF by myeloid and stromal cells

PMMA particles have been shown to stimulate osteoclastogenesis *in vitro*, at least in part by induction of RANKL and TNF, and by activation of NF- κ B and MAP kinases [24, 25]. However, the osteolytic response *in vivo* comprises a wide range of cell types and circulating factors considered to be active constituents of inflammatory osteolysis. The flux of inflammatory and immune cells in response to PMMA particles involves robust secretion of chemokines and other factors by mesenchymal, myeloid and endothelial cells. We hypothesized that angiogenesis and angiogenic factors play a key role in the development and resolution of the inflammatory and osteolytic responses by promoting influx of inflammatory cells.

To investigate this, we first examined the expression of VEGF in myeloid and mesenchymal lineage cells in response to treatment with PMMA particles, which have been shown to evoke inflammatory and osteoclastogenic responses [8, 24, 26]. As seen in Figure 1, both ST2 cells and BMMs expressed very little VEGF at baseline, but treatment with PMMA particles induced higher levels of VEGF expression, indicating that the PMMA-induced inflammatory cascade stimulates bone marrow macrophages and ST2 mesenchymal cells to produce VEGF. Notably, VEGF expression in ST2 lineages appeared to increase with time upon treatment with PMMA, signifying a possible dose responsiveness of stromal cells to PMMA.

3.2. PMMA particles induce angiogenesis and expression of angiogenic factors in the calvarium, a process attenuated by VEGF neutralizing antibody

Next, we examined the expression of VEGF and the angiogenic Von Willebrand factor (vWF) by immunostaining of calvarial sections obtained from control and PMMA-implanted mice. Our results indicate a significant increase in VEGF expression (figure 2A) and angiogenesis as evident by increased vWF staining (figure 2B) in calvariae from PMMA-treated animals compared to controls. These findings validate the *in vitro* results that PMMA particles can induce VEGF expression.

We further investigated if this activity of VEGF was due to signaling downstream of the VEGFR. To this end, we concomitantly treated PMMA-implanted mice with a VEGF neutralizing antibody or IgG control antibody. VEGF neutralization attenuated angiogenesis as seen by the lack of vWF staining compared with positive staining evident in figure 2 (figure 3).

This demonstrates that the PMMA-induced pro-angiogenic properties of VEGF within bone were a result of direct interaction of VEGF with a VEGFR.

3.3. Neutralizing VEGF abrogates PMMA-induced inflammation and calvarial osteoclast mediated osteolysis in mice.

We then sought to determine if VEGF-mediated angiogenesis was critical for the infiltration of inflammatory and immune cells and osteolysis in response to PMMA, and if VEGF-neutralization was sufficient to prevent this process. To address this proposition, we injected control and PMMA-implanted mice with either a VEGF neutralizing Ab or control IgG for 8 days. Histological analysis shows that PMMA particles induce inflammatory and osteolytic response when compared with control mice. PMMA treatment results in increase in TNF staining (figure 4A; *middle panel*), inflammatory and immune cell infiltration (Figure 4B, *top panel; asterisk*), bone resorbing TRAP-positive osteoclast (Figure 4B, *top panel; arrows*) and large area of focal bone loss. Interestingly VEGF neutralization significantly abrogated PMMA-induced increase in TNF expression (Figure 4A; *bottom panel*), plummeted inflammatory responses and halted osteoclast mediated bone loss (Figure 4B; *bottom panel*). These findings further confirm that VEGF acts as a key factor to mediate PMMA particles-induced osteolysis. Thus, regulating VEGF bioavailability or activity can be a highly effective method for preventing osteolysis associated with aseptic joint loosening.

4. Discussion

Over the past 20 years, research into osteoarthritis and inflammation has shed light on many crucial signaling molecules and their relationships to macrophages and other cells involved in bone metabolism. Some of these, such as RANKL and TNF, have been studied extensively and their mechanisms are now much better understood. However, the crucial role of other factors such as VEGF has been also described. In 1999, Gerber et al. demonstrated that the process of endochondral ossification and subsequent bone lengthening is dependent on VEGF expression causing angiogenesis and blood vessel invasion[27]. They also found that VEGF expression seemed to recruit chondroclasts to the growth plate, and when VEGF activity was blocked with a VEGF receptor chimeric protein, cartilage resorption and bone growth/growth plate lengthening did not occur. This demonstrated that VEGF and angiogenesis are necessary for bone generation and remodeling, establishing the role of VEGF as a growing area of interest. Further, it was shown that under inflammatory conditions, exposure to orthopedic particles lead to increased VEGF expression both at the mRNA and protein levels [5, 28] and regulation of osteoclasts. These studies lend credence to the critical role of VEGF in homeostatic bone generation and regeneration as well as its contribution to inflammatory, particle-induced, osteolysis.

This study sheds further insight into the role of VEGF in inflammatory osteolysis. We provide evidence that PMMA particles induce both angiogenic and pro-inflammatory responses via expression of VEGF and TNF, respectively, in murine osteoclast progenitors and mesenchymal cells. As we demonstrated, treatment of murine calvariae with PMMA particles lead to a significant increase in vWF expression, indicating a strong angiogenic response to PMMA. Based on our findings, the angiogenic environment is initiated not only through VEGF expression in bone marrow macrophages, but also by mesenchymal cells, which go on to compose a significant proportion of the non-hematopoietic cells in the marrow space. Multiple groups have previously demonstrated the variety of cells involved in the production of and reaction to VEGF as it relates to osteolysis. Yang et al. were able to show that bone marrow-derived mesenchymal stem cells produced VEGF in response to inflammatory cytokines [29]. Other groups have investigated and shown that osteoblasts, osteoclasts, and neutrophils all can react to or produce VEGF, leading to osteolysis [5]. These wide cellular responses are expected due to the non-specific nature of implant debris action, supporting the notion that orthopedic particles have the potential to elicit angiogenic and pro-inflammatory responses in numerous cell types around the implant site. The widespread expression of VEGF in response to PMMA throughout the bone microenvironment suggests that targeting of specific cells is likely to be ineffective in treating implant-osteolysis, and requires broad VEGF inhibition to prevent bone loss.

While the role of VEGF in promoting inflammation is well known, the mechanistic details of VEGF effect on bone cells remain vague. We display that angiogenesis is a process central to peri-prosthetic osteolysis since blocking VEGF function using a neutralizing antibody *in vivo* blocked both angiogenesis and osteolysis. Using immunostaining and antibody neutralizing studies, *in vivo*, we provide evidence that the pro-osteolytic effects of VEGF are likely due to a direct physical interaction between VEGF and its receptor on myeloid and stromal cells. Moreover, the fact that blocking VEGF is sufficient to ameliorate

the osteolytic response suggests that angiogenic activity in response to PMMA particles is critical for bone loss via recruitment of inflammatory cells and mediators (figures 3 and 4). This influx of inflammatory cytokines helps promote osteoclast formation and inhibits bone-forming cells.

Our results demonstrate that targeting VEGF using neutralizing antibody provides important intervention advantage and may be highly beneficial slowing implant loosening and the need for revision surgery. However, more studies are required to address potential side effects and utility of such approach in humans. Moreover, the exact mechanism of VEGF/VEGFR interactions is still unclear. In this regard, VEGF-receptors (VEGFR) are known to have at least 3 different isoforms, and VEGF is known to bind to both VEGFR1 and VEGFR2, both of which are present on cells in the bone marrow. VEGFR1 has complex functions in modulating and promoting angiogenesis and VEGFR2 has been shown to be predominantly proangiogenic[11, 15, 30]. Hence, binding to and blocking VEGF itself rather than targeting VEGFRs affords us the certainty of directly and specifically blocking its effects avoiding uncertain downstream receptor signaling. Nevertheless, elucidating the individual specific effects of each VEGFR on osteolysis stands as an important topic for future research to help us better understand the effects of VEGF on Osteoclasts, BMMs, and other cells involved in the bone resorption process. In addition, knowledge of specific VEGFR signaling in relation to bone loss will allow for the development of more targeted therapeutics for treating implant osteolysis that can spare beneficial functions of VEGF while inhibiting pro-inflammatory properties. Nonetheless, we demonstrate that use of VEGF neutralizing antibody can inhibit a robust, cellular inflammatory response and osteolysis in response to PMMA.

Although the murine calvarial osteolysis model has certain limitations in its representation of human implant-mediated osteolysis, it has been consistently used to study cellular mechanisms of osteolysis. We believe that there is sufficient evidence to suggest that VEGF-mediated angiogenesis plays a vital role in the PMMA-induced inflammatory osteolytic process and poses a potent therapeutic target. However, there still exists the need for further study of PMMA particles in different model systems to better understand the role of angiogenesis in implant failure. In sum, our study highlights the role of angiogenesis in the development of post-implant inflammatory osteolysis and the potential therapeutic benefits of blocking excessive VEGF during inflammation.

Acknowledgments

This work was supported by NIH/NIAMS R01-AR049192, R01-AR054326, R01-AR072623, (to YA), Biomedical grant #86200 from Shriners Hospital for Children (YA), and Pilot & Feasibility grant from P30 AR057235 NIH Core Center for Musculoskeletal Biology and Medicine (to GS)

References:

- [1]. Mbalaviele G, Novack DV, Schett G, Teitelbaum SL, Inflammatory osteolysis: a conspiracy against bone, *J Clin Invest* 127(6) (2017) 2030–2039. [PubMed: 28569732]
- [2]. Appel AM, Sowder WG, Siverhus SW, Hopson CN, Herman JH, Prosthesis-associated pseudomembrane-induced bone resorption, *Br J Rheumatol* 29(1) (1990) 32–6. [PubMed: 2306571]

- [3]. Chiba J, Schwendeman LJ, Booth RE Jr., Crossett LS, Rubash HE, A biochemical, histologic, and immunohistologic analysis of membranes obtained from failed cemented and cementless total knee arthroplasty, *Clin Orthop Relat Res* (299) (1994) 114–24. [PubMed: 8119005]
- [4]. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon AM, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari G, Drewes G, Gavin AC, Jackson DB, Joberty G, Neubauer G, Rick J, Kuster B, Superti-Furga G, A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway, *Nat Cell Biol* 6(2) (2004) 97–105. [PubMed: 14743216]
- [5]. Xiao C, He P, Han J, Tang M, Wang Z, Mi Y, Liu X, 1,3-Dichloro-2-propanol evokes inflammation and apoptosis in BV-2 microglia via MAPKs and NF-kappaB signaling pathways mediated by reactive oxygen species, *Toxicol Lett* 284 (2018) 103–112. [PubMed: 29248572]
- [6]. Swarnkar G, Abu-Amer Y, Regulation of NF-kappaB signaling in osteoclasts and myeloid progenitors, *Methods Mol Biol* 1280 (2015) 527–42. [PubMed: 25736770]
- [7]. Zhang Y, Xu S, Li K, Tan K, Liang K, Wang J, Shen J, Zou W, Hu L, Cai D, Ding C, Li M, Xiao G, Liu B, Liu A, Bai X, mTORC1 Inhibits NF-kappaB/NFATc1 Signaling and Prevents Osteoclast Precursor Differentiation, *In Vitro and In Mice*, *J Bone Miner Res* 32(9) (2017) 1829–1840. [PubMed: 28520214]
- [8]. Yamanaka Y, Abu-Amer W, Foglia D, Otero J, Clohisy JC, Abu-Amer Y, NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis, *J Orthop Res* 26(12) (2008) 1577–84. [PubMed: 18655139]
- [9]. Grosso A, Burger MG, Lunger A, Schaefer DJ, Banfi A, Di Maggio N, It Takes Two to Tango: Coupling of Angiogenesis and Osteogenesis for Bone Regeneration, *Front Bioeng Biotechnol* 5 (2017) 68. [PubMed: 29164110]
- [10]. Portal-Nunez S, Lozano D, Esbrit P, Role of angiogenesis on bone formation, *Histol Histopathol* 27(5) (2012) 559–66. [PubMed: 22419020]
- [11]. Shibuya M, Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases, *J Biochem* 153(1) (2013) 13–9. [PubMed: 23172303]
- [12]. Harry LE, Paleolog EM, From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis, *Birth Defects Res C Embryo Today* 69(4) (2003) 363–74. [PubMed: 14745976]
- [13]. Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, Hanada K, Kumegawa M, Hakeda Y, Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts, *FEBS Lett* 473(2) (2000) 161–4. [PubMed: 10812066]
- [14]. Tombran-Tink J, Barnstable CJ, Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone, *Biochem Biophys Res Commun* 316(2) (2004) 573–9. [PubMed: 15020256]
- [15]. Hu K, Olsen BR, The roles of vascular endothelial growth factor in bone repair and regeneration, *Bone* 91 (2016) 30–8. [PubMed: 27353702]
- [16]. Hu K, Olsen BR, Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair, *J Clin Invest* 126(2) (2016) 509–26. [PubMed: 26731472]
- [17]. Yang Q, McHugh KP, Patntirapong S, Gu X, Wunderlich L, Hauschka PV, VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin, *Matrix Biol* 27(7) (2008) 589–99. [PubMed: 18640270]
- [18]. Trebec-Reynolds DP, Voronov I, Heersche JN, Manolson MF, VEGF-A expression in osteoclasts is regulated by NF-kappaB induction of HIF-1alpha, *J Cell Biochem* 110(2) (2010) 343–51. [PubMed: 20432243]
- [19]. Nagao M, Hamilton JL, Kc R, Berendsen AD, Duan X, Cheong CW, Li X, Im HJ, Olsen BR, Vascular Endothelial Growth Factor in Cartilage Development and Osteoarthritis, *Sci Rep* 7(1) (2017) 13027. [PubMed: 29026147]
- [20]. Watanabe K, Hirata M, Tominari T, Matsumoto C, Fujita H, Yonekura K, Murphy G, Nagase H, Miyaura C, Inada M, The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted

Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer, *J Biol Chem* 291(40) (2016) 20891–20899. [PubMed: 27539855]

- [21]. Nagai T, Sato M, Kobayashi M, Yokoyama M, Tani Y, Mochida J, Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis, *Arthritis Res Ther* 16(5) (2014) 427. [PubMed: 25230745]
- [22]. Nagai T, Sato M, Kutsuna T, Kokubo M, Ebihara G, Ohta N, Mochida J, Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair, *Arthritis Res Ther* 12(5) (2010) R178. [PubMed: 20868495]
- [23]. Hamilton JL, Nagao M, Levine BR, Chen D, Olsen BR, Im HJ, Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain, *J Bone Miner Res* 31(5) (2016) 911–24. [PubMed: 27163679]
- [24]. Abbas S, Clohisy JC, Abu-Amer Y, Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts, *J Orthop Res* 21(6) (2003) 1041–8. [PubMed: 14554217]
- [25]. Zhang H, Ricciardi BF, Yang X, Shi Y, Camacho NP, Bostrom MG, Polymethylmethacrylate particles stimulate bone resorption of mature osteoclasts in vitro, *Acta Orthop* 79(2) (2008) 281–8. [PubMed: 18484256]
- [26]. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL, Tumor necrosis factor- α mediates orthopedic implant osteolysis, *Am J Pathol* 154(1) (1999) 203–10. [PubMed: 9916934]
- [27]. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N, VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation, *Nat Med* 5(6) (1999) 623–8. [PubMed: 10371499]
- [28]. Ren WP, Markel DC, Zhang R, Peng X, Wu B, Monica H, Wooley PH, Association between UHMWPE particle-induced inflammatory osteoclastogenesis and expression of RANKL, VEGF, and Flt-1 in vivo, *Biomaterials* 27(30) (2006) 5161–9. [PubMed: 16814378]
- [29]. Yang KQ, Liu Y, Huang QH, Mo N, Zhang QY, Meng QG, Cheng JW, Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenic factors and promote prostate cancer growth, *BMC Cancer* 17(1) (2017) 878. [PubMed: 29268703]
- [30]. Rahimi N, VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy, *Front Biosci* 11 (2006) 818–29. [PubMed: 16146773]

Highlights

- PMMA particles induce expression of the VEGF in macrophages and ST2 stromal cells.
- PMMA-induced VEGF promotes calvarial osteoclast activity in inflammatory osteolysis.
- VEGF-nAb reduces TNF expression and decreases PMMA induced osteoclastogenesis.

Figure 2: VEGF-A expression and angiogenesis are elevated in calvarial sections of mice exposed to PMMA particles.

PMMA particles (1mg in 100ul of PBS) or vehicle were injected over calvaria of 6-week old C57BL6 mice (n=5). After 1 week, calvariae were collected, sectioned and stained with IgG, VEGF and vWF antibody. Representative images of VEGF (A) and vWF (B) expression are indicated by arrows.

Figure 3: Administration of VEGF neutralizing antibody (nAb) abrogates expression of angiogenic factors induced by PMMA in mouse calvaria.

Control and PMMA-treated mice described in figure 2 were injected over the calvaria with wither IgG or VEGF nAb (SC, 0.1mg/Kg BW/daily; n=5 each group) throughout the duration of the experiment (8 days). Mice were then sacrificed and calvarial sections were stained with vWF antibody.

Figure 4: Administration of VEGF neutralizing antibody inhibits PMMA induced calvarial osteolysis and inflammatory cytokine abundance.
 VEGF nAb (0.1mg/kg BW) or IgG were injected daily over the calvaria following PMMA or PBS injection (n=5). After 8 days, mice were sacrificed and calvariae was collected and processed for immunohistochemistry staining for TNF and TRAP. Representative images of TNF (A), TRAP staining (black arrows), osteolytic zones (yellow dotted lines) and immune infiltrate (asterisk) (B) are shown.